TScan Therapeutics (TCRX) Liabilities and Shareholders Equity (2020 - 2026)

TScan Therapeutics (TCRX) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $202.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 39.29% year-over-year to $202.0 million; the TTM figure through Mar 2026 stood at $991.6 million (down 30.5% YoY), while the FY2025 annual figure was $228.8 million, down 38.35% from the prior year.
• Liabilities and Shareholders Equity slipped to $202.0 million in Q1 2026 per TCRX's latest filing, from $228.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $374.9 million in Q2 2024 and bottomed at $152.4 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $258.7 million across 5 years, with a median of $262.2 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 107.93% — and 2026, when it sank 39.29%.
• TScan Therapeutics' Liabilities and Shareholders Equity stood at $199.1 million in 2022, then soared by 36.7% to $272.1 million in 2023, then surged by 36.37% to $371.1 million in 2024, then plunged by 38.35% to $228.8 million in 2025, then declined by 11.71% to $202.0 million in 2026.
• Business Quant data shows TCRX's Liabilities and Shareholders Equity at $202.0 million in Q1 2026, $228.8 million in Q4 2025, and $262.2 million in Q3 2025.